Merck & Co., Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Merck & Co., Inc. – Product Pipeline Review – 2016’, provides an overview of the Merck & Co., Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc.

The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Merck & Co., Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Merck & Co., Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Merck & Co., Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Merck & Co., Inc. Snapshot 8

Merck & Co., Inc. Overview 8

Key Information 8

Key Facts 8

Merck & Co., Inc. - Research and Development Overview 9

Key Therapeutic Areas 9

Merck & Co., Inc. - Pipeline Review 21

Pipeline Products by Stage of Development 21

Pipeline Products - Monotherapy 22

Pipeline Products - Combination Treatment Modalities 23

Pipeline Products - Partnered Products 24

Pipeline Products - Out-Licensed Products 28

Merck & Co., Inc. - Pipeline Products Glance 31

Merck & Co., Inc. - Late Stage Pipeline Products 31

Merck & Co., Inc. - Clinical Stage Pipeline Products 34

Merck & Co., Inc. - Early Stage Pipeline Products 38

Merck & Co., Inc. - Drug Profiles 42

(elbasvir + grazoprevir) 42

asenapine maleate 44

bezlotoxumab 45

desloratadine 46

diquafosol tetrasodium 48

fosaprepitant dimeglumine 50

insulin glargine 51

narlaprevir 53

pembrolizumab 54

(actoxumab + bezlotoxumab) 64

(atorvastatin calcium + ezetimibe) 65

(ceftolozane sulfate + tazobactam sodium) 66

(cilastatin sodium + imipenem + relebactam) 68

(doravirine + lamivudine + tenofovir disoproxil fumarate) 69

actoxumab 70

anacetrapib 71

corifollitropin alfa 73

doravirine 75

fidaxomicin 77

letermovir 81

odanacatib 82

omarigliptin 84

posaconazole 86

solithromycin 87

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract 90

tedizolid phosphate 93

V-212 96

V-920 98

verubecestat 101

vibegron 102

vorinostat 103

(grazoprevir + MK-3682 + MK-8408) 107

BQ-123 108

dalotuzumab 110

elbasvir + grazoprevir + MK-3682 113

grazoprevir 114

lomerizine 116

lonafarnib 117

mirtazapine ODT 119

MK-1029 120

MK-2206 121

MK-2206 + selumetinib sulfate 124

MK-7622 126

MK-8521 127

MK-8628 128

samatasvir 130

temozolomide 132

V-114 134

MK-3682 135

vorapaxar sulfate 137

CB-618 139

insulin human 140

MK-0752 141

MK-1075 143

MK-1248 144

MK-2048 145

MK-2248 146

MK-4166 147

MK-7680 148

MK-8189 149

MK-8242 150

MK-8291 152

MK-8408 153

MK-8507 154

MK-8591 155

MK-8666 156

MK-8723 157

MK-8876 158

Monoclonal Antibody for Autoimmune Diseases 159

NB-1008 160

rituximab biosimilar 161

Small Molecule 1 for Human Cytomegalovirus Infection 162

Small Molecule 2 for Human Cytomegalovirus Infection 163

V-160 164

V-180 165

BNC-375 167

CB-027 168

chikungunya (viral like particles) vaccine 169

DORA-12 170

Drug to Inhibit 11Beta-HSD1 for Hypertension 171

ETP-142 172

GP-4 173

GRA-1 175

J8-CRM197 176

mDX-400 177

MK-0429 178

MK-1966 179

MK-4256 180

MK-8267 181

MK-8745 182

MK-8825 183

MK-8970 184

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 185

Monoclonal Antibody for Cancer 186

MRK-003 187

MRK-1777 188

MRLB-11055 189

Proteins for Cancer, Autoimmune and Inflammatory diseases 190

PTC-512 191

PTC-725 192

PTC-971 193

PyP-1 194

respiratory syncytial virus vaccine 195

SCH-412348 196

SCH-546738 197

Small Molecule 3 for Human Cytomegalovirus Infection 198

Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 199

Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes 200

Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection 201

Small Molecule to Inhibit ROMK for Hypertension and Heart Failure 202

Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis 203

Small Molecules for Undisclosed Indications 204

Small Molecules to Agonize GPR119 for Metabolic Disorders 205

Small Molecules to Agonize M1 for Alzheimer’s Disease 206

Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 208

Small Molecules to Block Cav2.2 Channel for Chronic Pain 209

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases 210

Small Molecules to Inhibit DGAT1 211

Small Molecules to Inhibit DHFR for Septicaemia 212

Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours 213

Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 214

Small Molecules to Inhibit Renin for Hypertension 215

THPP-1 216

TROX-1 217

XEN-445 218

XL-499 219

Drug to Target GPCR for Undisclosed Indication 220

Kibdelomycin A 221

MK-8133 222

Monoclonal Antibodies for Undisclosed Indication 223

Monoclonal Antibody for Neurology 224

SCH-722984 225

Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication 226

Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections 227

Small Molecules to Inhibit IRAK4 for Inflammatory Diseases 228

Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation 229

Small Molecules to Inhibit NS5A for Hepatitis C 230

Small Molecules to Inhibit PPI for Undisclosed Indication 231

Undisclosed Biosimilars 233

Merck & Co., Inc. - Pipeline Analysis 234

Merck & Co., Inc. - Pipeline Products by Target 234

Merck & Co., Inc. - Pipeline Products by Route of Administration 240

Merck & Co., Inc. - Pipeline Products by Molecule Type 242

Merck & Co., Inc. - Pipeline Products by Mechanism of Action 243

Merck & Co., Inc. - Recent Pipeline Updates 248

Merck & Co., Inc. - Dormant Projects 323

Merck & Co., Inc. - Discontinued Pipeline Products 331

Discontinued Pipeline Product Profiles 333

Merck & Co., Inc. - Company Statement 343

Merck & Co., Inc. - Locations And Subsidiaries 345

Head Office 345

Other Locations & Subsidiaries 345

Appendix 376

Methodology 376

Coverage 376

Secondary Research 376

Primary Research 376

Expert Panel Validation 376

Contact Us 376

Disclaimer 377

List of Tables

List of Tables

Merck & Co., Inc., Key Information 19

Merck & Co., Inc., Key Facts 19

Merck & Co., Inc. – Pipeline by Indication, 2016 21

Merck & Co., Inc. – Pipeline by Stage of Development, 2016 32

Merck & Co., Inc. – Monotherapy Products in Pipeline, 2016 33

Merck & Co., Inc. – Combination Treatment Modalities in Pipeline, 2016 34

Merck & Co., Inc. – Partnered Products in Pipeline, 2016 35

Merck & Co., Inc. – Partnered Products/ Combination Treatment Modalities, 2016 36

Merck & Co., Inc. – Out-Licensed Products in Pipeline, 2016 39

Merck & Co., Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 40

Merck & Co., Inc. – Pre-Registration, 2016 42

Merck & Co., Inc. – Phase III, 2016 43

Merck & Co., Inc. – Phase II, 2016 45

Merck & Co., Inc. – Phase I, 2016 47

Merck & Co., Inc. – Preclinical, 2016 49

Merck & Co., Inc. – Discovery, 2016 52

Merck & Co., Inc. – Pipeline by Target, 2016 245

Merck & Co., Inc. – Pipeline by Route of Administration, 2016 252

Merck & Co., Inc. – Pipeline by Molecule Type, 2016 253

Merck & Co., Inc. – Pipeline Products by Mechanism of Action, 2016 254

Merck & Co., Inc. – Recent Pipeline Updates, 2016 259

Merck & Co., Inc. – Dormant Developmental Projects,2016 334

Merck & Co., Inc. – Discontinued Pipeline Products, 2016 342

Merck & Co., Inc., Subsidiaries 356

List of Figures

List of Figures

Merck & Co., Inc. – Pipeline by Top 10 Indication, 2016 21

Merck & Co., Inc. – Pipeline by Stage of Development, 2016 32

Merck & Co., Inc. – Monotherapy Products in Pipeline, 2016 33

Merck & Co., Inc. – Combination Treatment Modalities in Pipeline, 2016 34

Merck & Co., Inc. – Partnered Products in Pipeline, 2016 35

Merck & Co., Inc. – Out-Licensed Products in Pipeline, 2016 39

Merck & Co., Inc. – Pipeline by Top 10 Target, 2016 245

Merck & Co., Inc. – Pipeline by Top 10 Route of Administration, 2016 251

Merck & Co., Inc. – Pipeline by Top 10 Molecule Type, 2016 253

Merck & Co., Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 254

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports